UPDATE: Investigational New Drug, ATA3219, Receives FDA Approval for Lupus Nephritis Treatment Study

The new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) was approved for study by the U.S. Food and Drug Administration. The first trial participants are expected to be enrolled in the second half of 2024. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.

Read the announcement